Patient Demographics and Clinical Characteristics of Previously Reported Cases of Post-COVID-19 Vaccine Immunoglobulin A Nephropathy (IgAN)
| Study | Age, Sex, Race | SARS-CoV-2 Vaccine | Time of Flare-Up After COVID-19 Vaccine | Year IgAN First Diagnosed | Treatment | Gross Hematuria Events During Disease Course | Persistent Microscopic Hematuria | Proteinuria in 2020, g/d | Proteinuria Between SARS-CoV-2 Vaccine Doses, g/d | Proteinuria after Last SARS-CoV-2 Vaccine Dose, g/d |
|---|---|---|---|---|---|---|---|---|---|---|
| Rahim et al, 20218 | 52, F, Asian | BNT162b2 (Pfizer) | 24 hours after the second dose | 2017 | RAASi | Yes | N/R | 633.1 mg/ga | N/R | 2,411 mg/g after 48 hours, 1,441 mg/g after 5 daysa |
| Negrea and Rovin, 20219 | 38, F, W | mRNA-1273 (Moderna) | 8 to 24 hours after the second dose | 2005 | RAASi | At presentation; during 1 episode of gastroenteritis; occasionally after yearly influenza vaccine | Yes | 0.63 | 0.82 | 1.40 |
| 38, F, W | mRNA-1273 (Moderna) | 8 to 24 hours after the second dose | 2019 | Cyc + pred for 6 months, followed by RAASi | At presentation only | Yes | 0.43 | 0.59 | 0.4 | |
| Perrin et al, 202110 | 22, M, N/R | mRNA-1273 (Moderna) | Day 2 and day 25 after the first dose; day 2 after the second dose | 2019 | Steroids for 6 months followed by RAASi | No | Yes | 0.20 | 0.34 | 0.40 |
| 41, F, N/R | BNT162b2 (Pfizer) | Day 2 after the first dose (the patient refused the second dose) | 2005 | Tac, MPA, and steroids for kidney transplantation | Yes | Yes | 0 | 0.47 | 0.41 | |
| 27, F, N/R | BNT162b2 (Pfizer) | Day 2 after the second dose | 2020 | Steroid for 1 month followed by RAASi | No | No | 20 | 1.9 | 1.2 | |
| Horino, 202111 | 46, F, Asian | BNT162b2 (Pfizer) | 12 hours after the second dose | 4 years before | Prednisolone | Yes | No | N/R | N/R | Nephrotic range |
| Abramson et al, 202120 | 30, M, W | mRNA-1273 (Moderna) | Day 2 after the second dose | No history of IgAN | RAASi | At presentation | N/R | N/R | N/R | 0.8 |
| Anderegg et al, 202121 | 39, M, N/R | mRNA-1273 (Moderna) | Immediately after the second dose | No history of IgAN | Cyc + steroids | At presentation | Yes | N/R | N/R | Nephrotic range |
↵aUrine microalbumin/creatinine.
Cyc, cyclophosphamide; F, female; M, male; MPA, mycophenolic acid; N/R, not reported; pred, prednisone; RAASi, renin-angiotensin-aldosterone system inhibitor; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; tac, tacrolimus; W, White.